Related Experiment Videos
Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects
1Division of Pediatric Cardiology, Cardiothoracic Science Centre, AIIMS, Ansari Nagar, New Delhi.
Insights
Prostaglandin E1 (PGE1) is a life-saving medication for neonates with congenital heart defects requiring ductus arteriosus patency. This study highlights its effectiveness in stabilizing infants before surgery, despite potential side effects and high costs.
Area of Science:
- Neonatal Cardiology
- Pediatric Pharmacology
- Congenital Heart Disease
Background:
- E-type prostaglandins (PGE1) are crucial for maintaining ductus arteriosus patency in neonates.
- Ductus-dependent congenital heart disease (CHD) requires timely intervention for survival.
- PGE1 has been used for decades in Western countries but was introduced in India in 1995.
Purpose of the Study:
- To evaluate the efficacy and safety of Prostaglandin E1 (PGE1) in Indian infants with ductus-dependent congenital heart disease.
- To identify specific cardiac defects where PGE1 administration is beneficial.
- To assess the incidence and nature of side effects associated with PGE1 use in neonates.
Main Methods:
- A retrospective analysis of 43 infants aged 1-45 days with ductus-dependent CHD treated with PGE1.
- Continuous intravenous infusion of PGE1, starting at 0.05-0.4 ug/kg/min and reduced to 0.01 ug/kg/min post-effect.
- Monitoring for beneficial response and adverse events, including apnea, hypotension, hyperthermia, and seizures.
Main Results:
- A beneficial response to PGE1 was observed in 41 out of 43 infants (95.3%).
- The most common serious side effect was apnea, occurring in 5 of 32 spontaneously breathing infants (15.6%).
- PGE1 effectively stabilized infants with various ductus-dependent lesions, including pulmonary atresia, critical aortic stenosis, and transposition of the great arteries.
Conclusions:
- PGE1 is a highly effective and life-saving drug for stabilizing neonates with ductus-dependent congenital heart malformations.
- Careful dose titration is necessary to minimize side effects, particularly apnea.
- The high cost of PGE1 remains a significant barrier to its widespread and long-term use in India.
Abstract:
E-type prostaglandins (PGE1) can effectively maintain the patency of the ductus arteriosus in neonates. Its use, therefore can be life saving in infants born with ductus dependent congenital heart disease. Although PGE1 is available for over two decades in western world, it has been introduced in India only since April, 1995. Various cardiac defects where PGE1 is useful include (a) lesions with ductus dependent pulmonary blood flow e.g. pulmonary atresia with or without ventricular septal defect, critical valvular pulmonic stenosis etc, (b) lesions with ductus dependent systemic blood flow e.g. critical aortic stenosis, coarctation of aorta, interruption of aortic arch etc, and (c) admixture lesions like transposition of great arteries. The drug is given as a continuous intravenous infusion. The initial dose is 0.05 to 0.4 ug/kg/min, infusion rate must be decreased to 0.01 ug/kg/min as soon as the desired effect is achieved as incidence of side effects is more at higher doses. Serious side effects include apnoea, hypotension, hyperthermia, seizures etc. We have used this drug in 43 infants ranging in age from one to forty five days. Beneficial response was seen in 41 of 43 infants and the major side effect was apnoea (seen in 5 of 32 spontaneously breathing infants). Unfortunately the high cost of the drug prohibits its wide spread and long term use. PGE1 is a life saving drug for infants born with ductus dependent congenital cardiac malformations. It helps in stabilizing these patients prior to further surgical palliation or correction.